NASDAQ · VACC
Vaccitech plc
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
Loading market information…
NASDAQ · FSTX · USD
Stock price, earnings
Quote as of Mar 8, 2023, 09:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
F-star Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow F-star Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to inventing tetravalent bispecific antibodies for the treatment of cancer, particularly within the field of immuno-oncology. The company's primary investigational product, FS118, is currently in a Phase 2 proof-of-concept trial, evaluating its efficacy in head and neck cancer patients who have acquired resistance to PD-1/PD-L1 therapies. F-star is also advancing FS222, a bispecific antibody designed to simultaneously target the costimulatory CD137 receptor and the inhibitory PD-L1 ligand, through its initial Phase 1 human clinical study. Moreover, two additional drug candidates, FS120 and SB 11285, are undergoing Phase 1 clinical evaluation for patients with advanced malignancies. Founded in 2002, F-star Therapeutics, Inc. has its corporate headquarters situated in Cambridge, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:20 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2021 |
|---|
| Aug 12, 2021 |
| -$0.92-24.32% vs estimate |
| $0.00-100.0% vs estimate |
| Q1 2021 | May 17, 2021 | -$1.08+6.9% vs estimate | $2.92M-74.08% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$4.07+$0.01 (+0.12%)
Theseus Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.14% below the high.
$0.88-$0.08 (-8.0%)
Selecta Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.72% below the high.
$2.18+$0.02 (+0.93%)
Pardes Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.6% below the high.
$1.54-$0.02 (-1.28%)
NGM Biopharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.16% below the high.
$0.63+$0.04 (+7.29%)
Sesen Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.84% below the high.
$2.23+$0.04 (+1.83%)
Paratek Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.9% below the high.
$4.91-$0.04 (-0.81%)
Decibel Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 9.07% below the high.
